Burning Rock Biotech (BNR) Q1 2025 earnings summary

Executive summary

• Achieved commercial breakeven in 1Q25, excluding R&D, under new industry conditions, with commercial operations reaching profitability and significant reduction in operating cash outflow.

• Revenue for Q1 2025 rose 5.9% year-over-year to RMB 133.1 million, driven by strong pharma R&D services growth.

• Net loss narrowed significantly to RMB 13.5 million from RMB 121.5 million a year ago, reflecting improved cost controls.

• Continued focus on sales efficiency, gross margin improvement, and cost reduction in G&A and R&D.

• Operating expenses dropped 46.8% year-over-year due to budget controls and headcount reduction.

Financial highlights

• 1Q25 revenues were RMB 133.1 million, up 6% year-over-year and 6% sequentially from 4Q24.

• Non-GAAP gross profit margin reached 75.7% in 1Q25, up from 74.3% in 1Q24.

• Gross profit increased 13.7% year-over-year to RMB 97.4 million.

• Adjusted EBITDA loss narrowed to RMB (3.9) million in 1Q25 from RMB (16.6) million in 4Q24.

• Cash balance at period-end was RMB 497 million, with operating cash outflow reduced to RMB 25 million in 1Q25.

Outlook and guidance

• Expect selling expense to remain below 40% of revenue going forward.

• Continued focus on margin improvement and disciplined investment in R&D.